Takamura S, et al. - Authors gauged the impacts of infliximab, ustekinumab and secukinumab on bodyweight (BW) and body mass index (BMI) in patients with psoriasis. The changes in BW and BMI among patients treated with these biologics at their hospital were retrospectively examined. In the patients with psoriasis, BW was increased by infliximab, whereas in these patients, ustekinumab and secukinumab do not affect the BW. The proportion of the patients who showed 75% or more improvement in the Psoriasis Area and Severity Index among the three groups was not seen to be different.